Takeda Pharmaceutical Co Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Takeda Pharmaceutical Company Limited, dated April 14, 2025, reports on share repurchase activities for the period from March 1, 2025, to March 31, 2025. The report is submitted pursuant to Rule 13a-16 of the Securities Exchange Act of 1934 and details transactions executed under a Board of Directors resolution approved on January 30, 2025.
Key Financial Metrics
The filing focuses exclusively on capital allocation via share buybacks and does not provide operational financial metrics such as revenue, profit, cash flow, margins, or debt levels.
- Total Repurchase Authorization: 28,500,000 shares with a total budget of JPY 100,000,000,000.
- Repurchases in Reporting Month (March 2025): 6,148,200 shares for a total cost of JPY 27,179,686,700.
- Aggregate Repurchases to Date: 11,543,600 shares for a total cost of JPY 49,977,908,700.
- Progress of Repurchase Program: 40.50% of authorized shares and 49.98% of authorized value utilized as of March 31, 2025.
- Treasury Shares Held: 11,734,484 shares as of March 31, 2025.
- Total Issued Shares: 1,590,949,609 shares.
Material Changes
The filing does not contain comparative data against prior periods to assess material changes in financial performance. The primary activity reported is the execution of the ongoing share repurchase program, with daily transactions occurring between March 3 and March 12, 2025.
Guidance, Outlook, and Risks
The document does not provide management commentary, financial guidance, or risk factors. It strictly reports the status of the share repurchase resolution approved on January 30, 2025, which allows for open-market repurchases through a trust bank until May 31, 2025. No unusual items or contingencies are disclosed in this specific report.
Investor Verification Checklist
- Verify the remaining duration of the repurchase program (ends May 31, 2025) and the remaining budget (approx. JPY 50 billion).
- Confirm the average price per share paid during the March 2025 reporting period (approx. JPY 4,421 per share).
- Review the total number of treasury shares held (11,734,484) to understand the impact on diluted share count.
- Note that the filing does not include operational results; refer to the latest Form 20-F or quarterly earnings release for revenue and profit data.